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Background
Cluster headache (CH) is an extremely severe and debil-
itating trigemino-autonomic pain syndrome.About 10%
of patients with CH manifest a chronic form CH (CCH).
Extracts of Boswellia serrata have been clinically studied
for the treatment of many inflammatory conditions such
as osteoarthritis and rheumatoid arthritis (3). The resin
from Boswellia Serrata contains a number of biological
actives called pentacyclic triterpene acids, which give the
extract its anti-inflammatory and analgesic properties,
with boswellic acid the major active ingredient (4).
These acids have been demonstrated to interfere with
the body’s natural inflammatory response by inhibiting
cytokines and leukocyte activity. The present study aims
to evaluate the long-term efficacy of Boswellia Serrata
(Sallaki H15) on headaches and disturbed sleep in
patients with CCH.
Results
In an open-label study, 4 patients with CCH and dis-
turbed sleep received oral Boswellia Serrata.
Conclusion
The effects were long-lasting in 3 patients (mean 15 months)
and transient (6 months) in one patient. The rapid improve-
ment of nocturnal pain within weeks is similar to the analge-
tic effect observed in recent trials using Boswellia Serrata in
cancer pain The mechanisms of how Boswellia Serrata
reduces pain in CCH remain unclear. Boswellic acids,
constituents of Boswellia extract have subsequently been
identified as selective redox independent noncompetitive
inhibitors of both 5-lipoxygenase, the key enzyme in leuko-
triene biosynthesis and human leukocyte elastase.
Proinflammatory cytokines, such as leukotrienes, are known
to play a role in the pathophysiology of CH. This study
provides Class IV evidence that oral Boswellia Serrata
(Sallaki H15) reduces the intensity and frequency of
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